The combination of interleukin 2 (IL-2) and antiretroviral therapy (ART) represents an emerging strategy in the treatment of patients infected with HIV. Aside from its immunomodulatory role, however, IL-2 may induce replication of human herpesvirus 8 (HHV-8)/Kaposi sarcoma (KS)-associated herpesvirus. We retrospectively evaluated HHV-8 plasma viremia and cellular load, as well as anti-HHV-8 antibody titers, in sequential samples from 84 patients receiving ART alone or in combination with IL-2. At baseline, HHV-8 plasma viremia was present only in 2 HHV-8-seropositive patients in whom KS subsequently developed during or immediately after termination of IL-2 therapy. The level of viremia increased during follow-up and peaked at the time of the clinical manifestation of KS. Moreover, transient peaks of HHV-8 viremia were temporally associated with administration of IL-2. HHV-8 plasma viremia was never detected in the other 47 patients receiving IL-2 nor in 35 controls treated only with ART. Thus, IL-2 therapy seems safe in most patients infected with both HIV and HHV-8, except for those with detectable HHV-8 viremia, who may not be eligible for IL-2 treatment. (C) 2002 by The American Society of Hematology.

Malnati, M., Broccolo, F., Nozza, S., Sarmati, L., Ghezzi, S., Locatelli, G., et al. (2002). Retrospective analysis of HHV-8 viremia and cellular viral load in HIV-seropositive patients receiving interleukin 2 in combination with antiretroviral therapy. BLOOD, 100(5), 1575-1578.

Retrospective analysis of HHV-8 viremia and cellular viral load in HIV-seropositive patients receiving interleukin 2 in combination with antiretroviral therapy

SARMATI, LOREDANA;ANDREONI, MASSIMO;
2002-01-01

Abstract

The combination of interleukin 2 (IL-2) and antiretroviral therapy (ART) represents an emerging strategy in the treatment of patients infected with HIV. Aside from its immunomodulatory role, however, IL-2 may induce replication of human herpesvirus 8 (HHV-8)/Kaposi sarcoma (KS)-associated herpesvirus. We retrospectively evaluated HHV-8 plasma viremia and cellular load, as well as anti-HHV-8 antibody titers, in sequential samples from 84 patients receiving ART alone or in combination with IL-2. At baseline, HHV-8 plasma viremia was present only in 2 HHV-8-seropositive patients in whom KS subsequently developed during or immediately after termination of IL-2 therapy. The level of viremia increased during follow-up and peaked at the time of the clinical manifestation of KS. Moreover, transient peaks of HHV-8 viremia were temporally associated with administration of IL-2. HHV-8 plasma viremia was never detected in the other 47 patients receiving IL-2 nor in 35 controls treated only with ART. Thus, IL-2 therapy seems safe in most patients infected with both HIV and HHV-8, except for those with detectable HHV-8 viremia, who may not be eligible for IL-2 treatment. (C) 2002 by The American Society of Hematology.
2002
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore MED/17 - MALATTIE INFETTIVE
English
Con Impact Factor ISI
antiretrovirus agent; interleukin 2; virus antibody; adult; article; controlled study; dose response; female; follow up; herpes; human; Human herpesvirus 8; Human immunodeficiency virus; Human immunodeficiency virus infection; immunomodulation; major clinical study; male; priority journal; serology; treatment outcome; treatment planning; viremia; virus load; virus replication; Adult; Aged; Anti-HIV Agents; Drug Therapy, Combination; Female; Herpesvirus 8, Human; HIV Seropositivity; HIV-1; Humans; Interleukin-2; Male; Middle Aged; Retrospective Studies; Viral Load; Viremia
Malnati, M., Broccolo, F., Nozza, S., Sarmati, L., Ghezzi, S., Locatelli, G., et al. (2002). Retrospective analysis of HHV-8 viremia and cellular viral load in HIV-seropositive patients receiving interleukin 2 in combination with antiretroviral therapy. BLOOD, 100(5), 1575-1578.
Malnati, M; Broccolo, F; Nozza, S; Sarmati, L; Ghezzi, S; Locatelli, G; Delfanti, F; Capiluppi, B; Careddu, A; Andreoni, M; Monini, P; Poli, G; Lazzar...espandi
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/49469
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 12
social impact